Option chain shows key data for a2 Milk Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for a2 Milk Co.

a2 Milk Co (OTC:ACOPY) Stock, Option Chain

A2 Milk is a New Zealand licensor and marketer of fresh milk, infant formula, and other dairy products that lack the A1 beta-casein protein. The firm was founded in 2000 by Corran McLachlan, who developed a genetic test to determine which proteins a cow produces in its milk, and business partner Howard Paterson. The company has been through a tumultuous history of receivership, legal battles, and strategic shifts, but emerged in its current structure in 2006 and listed publicly in March 2013.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Intraday Update

Markets

Movers

Trading Ideas

ACDVF

ACIA

ACKRF

ACOPF

ADUS

AGYS

AKAM

ALIAF

ANIP

APLS

ARCC

ARCT

ARNA

ARPC

ATEN

AZUL

BHFAP

BUROF

CABO

CAGDF

CASH

CBRE

CCNI

CDAY

CINF

CNMD

CNNEF

CTAS

CWST

CYTK

DENN

DRGDF

DSNKY

DXCM

EBAYL

EGOV

EMCI

ENPH

ENSG

EORZ

EVBG

EXETF

EXLS

EXPO

FBPRM

FCAP

FISV

FUNC

GMICF

GNRC

GRFS

GREENWAY TECHNOLOGIES INC by Greenway Technologies, Inc.

GWTI

HALL

HCAT

HMCBF

HOLX

HURN

HWKN

IOSP

IRET

JBSS

JJSF

Stocks That Managed to Breach 52-Week Highs Wednesday Morning

THE A2 MILK CO UNSP/ADR by The A2 Milk Co Ltd.

The a2 Milk Co Ltd

On Monday, Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/42942185/phio-pharmaceuticals-announces-promising-results-of-second-cohort-from-its-ongoing-clinical-study-o" rel="noreferrer noopener">or 100% tumor clearance</a>.
Phio&#8217;s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma.
Of the patients enrolled to date, six patients were diagnosed with cutaneous squamous cell carcinoma, and one patient was diagnosed with metastatic melanoma.
At Day 36 (tumor excision), while patients in the first cohort had stable disease, results are now available for the four patients who completed treatment in the 2nd&nbsp;cohort:
<ul>
<li>Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma.</li>
<li>Partial response (90% tumor clearance) is reported for one patient with cutaneous squamous cell carcinoma and one with stable disease, having not progressed.</li>
</ul>
No dose-limiting toxicities or clinically relevant treatment-emergent adverse events have occurred in the patients receiving intratumoral PH-762, and the intratumoral injections have been well tolerated.
Preclinical <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38363607/why-is-penny-stock-phio-pharmaceuticals-trading-higher-on-monday" rel="noreferrer noopener">studies demonstrated</a>:
<ul>
<li>PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME).</li>
<li>Intratumoral injection of murine PH-762 (mPH-762) significantly inhibits tumor growth in murine tumor models and is well-tolerated.</li>
<li>mPH-762-mediated silencing of PH-762 within the TME may generate memory-specific T cells, promoting IFN-γ release in the TME</li>
<li>Studies in non-human primates demonstrate that PH-762 is well-tolerated and does not induce the release of cytokines associated with cytokine release syndrome.</li>
</ul>
Price Action: PHIO stock is up 378.7% at $8.09 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" target="_blank" rel="noreferrer noopener">Like Bristol-Myers Squibb And AbbVie, Johnson &amp; Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal</a></li>
</ul>

Biotech

Health Care

General

PHIO

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

WIIM

SEMR

SEMrush shares are trading higher after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $17 to $20.

Lithia Motors's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) short percent of float has fallen 14.76% since its last report. The company recently reported that it has 1.98 million shares sold short, which is 8.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lithia Motors Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736790321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lithia Motors has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Lithia Motors's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lithia Motors's peer group average for short interest as a percentage of float is 9.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Lithia Motors's Recent Short Interest

Simon Property Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) short percent of float has fallen 7.02% since its last report. The company recently reported that it has 4.83 million shares sold short, which is 2.25% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Simon Property Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736790316_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Simon Property Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Simon Property Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Simon Property Group's peer group average for short interest as a percentage of float is 6.30%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Simon Property Group?

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has fallen 3.26% since its last report. The company recently reported that it has 11.17 million shares sold short, which is 2.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736790311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

AMGN

Peering Into Amgen's Recent Short Interest

Citigroup analyst Andrew Kaplowitz maintains Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) with a Buy and lowers the price target from $119 to $115.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Ingersoll Rand, Lowers Price Target to $115

NextEra Energy shares are trading lower after BMO Capital downgraded the stock from Outperform to Market Perform and cut its price target from $26 to $18.

<a href="https://www.bloomberg.com/news/articles/2025-01-13/eu-considers-expanding-probe-into-musk-s-x-digital-chief-says?utm_source=google&amp;utm_medium=bd&amp;cmpId=google">https://www.bloomberg.com/news/articles/2025-01-13/eu-considers-expanding-probe-into-musk-s-x-digital-chief-says?utm_source=google&amp;utm_medium=bd&amp;cmpId=google</a>
&nbsp;
The European Union is considering expanding its investigation into whether Elon Musk's X social network breached its content moderation rulebook, the bloc's top digital official said.

Macro Economic Events

Legal

Global

Economics

'EU Considers Expanding Probe Into Musk's X, Digital Chief Says' - Bloomberg News

Morgan Stanley analyst Brian Nowak maintains Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) with a Underweight and raises the price target from $34 to $35.

YELP

Morgan Stanley Maintains Underweight on Yelp, Raises Price Target to $35

ADMA

ADMA Biologics shares are trading lower. The company reported preliminary FY24 revenue results.

Citigroup analyst Andrew Kaplowitz maintains Illinois Tool Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) with a Neutral and lowers the price target from $279 to $265.

Citigroup Maintains Neutral on Illinois Tool Works, Lowers Price Target to $265

M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/MTB/earnings">opening bell on Thursday, Jan. 16, 2025.</a>
Analysts expect the Buffalo, New York-based company to report quarterly earnings at $3.74 per share, up from $3.60 per share in the year-ago period. M&amp;T Bank projects to report revenue of $2.34 billion for the recent quarter, compared to $2.3 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 6, M&amp;T Bank named Krista Phillips as Chief Customer Officer.
M&amp;T Bank shares fell 1.8% to close at $187.75 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/MTB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Truist Securities analyst Brian Foran initiated coverage on the stock with a Buy rating and a price target of $233 on Jan. 7, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Compass Point analyst David Rochester maintained a Neutral rating and boosted the price target from $220 to $250 on Dec. 10, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Keefe, Bruyette &amp; Woods analyst David Konrad maintained a Market Perform rating and raised the price target from $205 to $221 on Dec. 4, 2024. This analyst has an accuracy rate of 73%.</li>
<li>JP Morgan analyst Steven Alexopoulos downgraded the stock from Overweight to Neutral and raised the price target from $215 to $223.5 on Dec. 4, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Piper Sandler analyst Frank Schiraldi maintained an Overweight rating and boosted the price target from $205 to $243 on Nov. 27, 2024. This analyst has an accuracy rate of 77%.</li>
</ul>
Considering buying MTB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-1024x592.png" alt="" class="wp-image-730254" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13062616/image-68.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

M&T Bank Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Morgan Stanley analyst Neel Kumar maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Equal-Weight and lowers the price target from $155 to $130.

Morgan Stanley Maintains Equal-Weight on Westlake, Lowers Price Target to $130

AKBA

Akebia Therapeutics shares are trading higher after the company announced near 100% U.S. dialysis coverage for Vafseo with a Phase 3 trial for late-stage non-dialysis CKD patients planned for mid-2025.

Citigroup analyst Vladimir Bystricky maintains IDEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) with a Buy and lowers the price target from $269 to $267.

Citigroup Maintains Buy on IDEX, Lowers Price Target to $267

Morgan Stanley analyst Matthew Cost maintains Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Equal-Weight and lowers the price target from $17.5 to $16.

WBTN

Morgan Stanley Maintains Equal-Weight on Webtoon Entertainment, Lowers Price Target to $16

SHAK

Shake Shack shares are trading lower. The company reported preliminary Q4 reuslts.

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is navigating rocky market terrain, with<a href="https://www.benzinga.com/quote/TSLA/news"> its stock price</a> slipping nearly 12% in the past month.
Despite the dip, analysts like Morgan Stanley&#8217;s Adam Jonas remain upbeat. The analyst raised his <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">price target to $430</a> and reiterated Tesla as a &#8220;Top Pick&#8221; for investors Monday.
<h1 class="wp-block-heading">Tesla Stock Price Target Raised By Morgan Stanley</h1>
The bullish move is anchored on Tesla&#8217;s expansion into autonomous rideshare and embodied AI sectors — a game-changing frontier for the EV giant.
Jonas highlighted Tesla's unique advantages, noting, "We see embodied AI as the driver for upside to the revised $800 bull case." Tesla&#8217;s integration of robotics, AI, and energy storage — boosted by Elon Musk's cross-company synergy with SpaceX and xAI — positions the company as a standout player in the evolving global mobility market.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/01/42938578/jamie-dimon-calls-elon-musk-an-extraordinary-talent-jp-morgan-ceo-shares-why-trumps-election-victory-didnt-surprise-him">Jamie Dimon Calls Elon Musk &#8216;An Extraordinary Talent&#8217; — JP Morgan CEO Shares Why Trump&#8217;s Election Victory Didn&#8217;t Surprise Him</a>
<h1 class="wp-block-heading">Tesla Stock Chart Signals Mixed Bag</h1>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="494" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13103748/Screenshot-2025-01-13-at-9.07.17-PM.png" alt="" class="wp-image-730782" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13103748/Screenshot-2025-01-13-at-9.07.17-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13103748/Screenshot-2025-01-13-at-9.07.17-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011325&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Technically, Tesla presents a conundrum. While its price of $387.90 falls below both the eight-day ($397.07) and 20-day ($423.36) simple moving averages (SMAs), signaling a short-term bearish signal, the long-term view is more optimistic. The 50-day SMA at $367.59 and a significantly lower 200-day SMA at $246.63 suggest buying momentum.
Tesla's MACD (moving average convergence/divergence) indicator at 5.40 and an RSI (relative strength index) of 46.92 hover in neutral territory, leaving traders on edge about the stock's next move.
<h1 class="wp-block-heading">Robotaxi Expansion: The Next Frontier</h1>
Tesla's mobility ambitions aren't just hype. Jonas believes the company&#8217;s autonomous rideshare services will drive high-margin, recurring revenue streams. "The &gt;1 billion miles traveled per day we forecast Tesla will achieve by 2030 positions it uniquely," Jonas remarked, underscoring Tesla&#8217;s ability to leverage its fleet data to stay ahead in the competitive autonomous vehicle landscape.
While the stock's immediate path remains murky, Tesla's futuristic gambit on embodied AI and robotaxi fleets has bulls betting on long-term gains. Investors, it seems, are strapping in for the ride.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42950414/tesla-stock-sold-by-europes-largest-pension-fund-in-q3-we-had-a-problem-with-musk-pay">Tesla Stock Sold By Europe&#8217;s Largest Pension Fund In Q3: &#8216;We Had A Problem&#8217; With Musk Pay</a></li>
</ul>
Photo: Courtesy Tesla

Long Ideas

Technicals

Tech

TSLA

Tesla Embodied AI, Robotaxi Dreams Propel Bullish Sentiment: Stock Chart Flashes Mixed Signals

Citigroup analyst Andrew Kaplowitz maintains Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) with a Buy and lowers the price target from $268 to $266.

Citigroup Maintains Buy on Honeywell Intl, Lowers Price Target to $266

Keefe, Bruyette &amp; Woods analyst Aidan Hall maintains T. Rowe Price Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Market Perform and lowers the price target from $116 to $111.

TROW

Keefe, Bruyette & Woods Maintains Market Perform on T. Rowe Price Gr, Lowers Price Target to $111

The a2 Milk Company Limited (ACOPF) Q2 2024 Earnings Call Transcript

The a2 Milk Company: Current Nutritional Science Suggests It's A Long-Term Sell

The a2 Milk Company Limited (ACOPF) Q4 2024 Earnings Call Transcript

The a2 Milk Company: Maiden Dividend And Financial Prospects Are Key Considerations

ACOPY

a2 Milk Co

Comments

a2 Milk Co

a2 Milk Co (ACOPY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga